Nivolumab (NIVO) + ipilimumab (IPI) versus platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (aNSCLC): 3-year update from CheckMate 227 part 1 Meeting Abstract
| Authors: | Ramalingam, S. S.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Zurawski, B.; Audigier-Valette, C.; Provencio, M.; Linardou, H.; Kim, S. W.; Borghaei, H.; Hellmann, M. D.; O'Byrne, K. J.; Paz-Ares, L. G.; Reck, M.; Nathan, F. E.; Brahmer, J. R. |
| Abstract Title: | Nivolumab (NIVO) + ipilimumab (IPI) versus platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (aNSCLC): 3-year update from CheckMate 227 part 1 |
| Meeting Title: | 2020 North America Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 16 |
| Issue: | 1 Suppl. |
| Meeting Dates: | 2020 Oct 16-17 |
| Meeting Location: | Virtual |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-01-01 |
| Start Page: | S2 |
| End Page: | S3 |
| Language: | English |
| ACCESSION: | WOS:000610079600003 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2020.10.023 |
| Notes: | Meeting Abstract: OA03.03 -- Source: Wos |
